Thread by @ADesaiMD

Folks! We return for #HOTrainees with the exciting #Day2 @myESMO #ESMO20 and some more #practice relevant studies in #breastcancer #ProstateCancer #lungcancer #GI, so sit back, relax and lets go through some data (#HO #trainee-style!) Shout out to @peters_solange @OncoAlert

1. #BreastCancer: We have #monarchE and #IMPassion031 hoping to hear from experts @ErikaHamilton9 @NicoleKuderer @DrSGraff @matteolambe @tmprowell @GeorgeSledge51 @VukovicPetra for more insights- please link to your discussions here for #trainees:

1. A) #monarchE: use of #abemiciclib in HR+, HER2-,high risk #EBC in addition to endocrine therapy.
Current #SOC: adjuvant ET (5-10 years)
#monarchE: #Abemaciclib + ET iDFS HR 0.747, here's a great summary by @ErikaHamilton9 for @OncoAlert :

https://twitter.com/OncoAlert/status/1307744623411056644?s=20

1. B) #IMPassion031 studies #neoadj #atezolizumab + chemo in early #TNBC showed #pCR in 57.6% pts with atezo+chemo vs 41.1% benefit regardless of PD-L1 status
Current SOC: #Neoadj #Chemo, algorithm below cc: @UpToDate, discussion by @matteolambe @OncoAlert

https://twitter.com/OncoAlert/status/1307732812901093377?s=20

2. #ProstateCancer: #PROfound and #IPATential both in the mCRPC space @quimmateo , hoping to hear from experts @PGrivasMDPhD @DrChoueiri @neerajaiims @montypal @TiansterZhang @shilpaonc for more insights- please link to your discussions here for #trainees:

2. A) #PROfound looks at #OS analysis of patients #prostatecancer w/ #olaparib vs #abi/#enza. Better responses in pts w/ BRCA1/2, less clear benefit for pts w/ CDK12/ATM mutations
Current #SOC: @NCCN 2nd line: Docetaxel?- need some #expert help!

More discussion on #evidence and some #questions to think about can be found here:
@TheWonkologist:

https://twitter.com/TheWonkologist/status/1307750424972271617?s=20

@VPrasadMDMPH:

https://twitter.com/VPrasadMDMPH/status/1307742709432479744?s=20

Paper @NEJM: nejm.org/doi/full/10.10… and one out today with #survival data: nejm.org/doi/full/10.10…

2. B) #IPATential150 trial: #Abiraterone +/- #Ipatasertib (Had to look up #MOA below:) in mCRPC, good data for #PTEN loss but needs more OS/other #endpoints data

3. #LungCancer and #CRC had data presented and published @NEJM: nejm.org/doi/full/10.10…, discussion found here: @OncLive onclive.com/view/sotorasib…

Great list of #concomitant #pubs from #ESMO20 by @aftimosp here:

https://twitter.com/aftimosp/status/1307747772423180290?s=20

#ADAURA >>>@NEJM
#Sotorasib phase 1 >>> @NEJM
#PROfound >>>@NEJM
#IMpassion031 >>>@TheLancet
#monarchE>>> J Clin Oncol @ASCO_pubs

Hoping this will summarize some #key #studies for fellow #HOTrainees from #ESMO20 #Day2 @MayoHemeOnc @arkhaki @ArielleElkrief @guptaarjun90 @HOJournalClub @hfuentesbayne @AnaVManana @RahulBanerjeeMD @ShuchiGulati @inas_md @OncoAlert